Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. …

… Simonneau has received honoraria and research grants from Actelion, Bayer Schering,
GlaxoSmithKline, Pfizer, and United Therapeutics. Dr. Robbins has received grant/research …

Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary
hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥…

Thus, the task of writing Guidelines or Expert Consensus documents covers not only the
integration of the most recent research, but also the creation of educational tools and …

Background Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic
guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate–…

Background In patients with acute exacerbations of chronic obstructive pulmonary disease,
noninvasive ventilation may be used in an attempt to avoid endotracheal intubation and …

In 1998, during the Second World Symposium on Pulmonary Hypertension (PH) held in
Evian, France, a clinical classification of PH was proposed. The aim of the Evian classification …

Rationale: Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend
is for management in designated centers with multidisciplinary teams working in a shared-…

Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …

Objectives : We sought to determine the factors associated with long-term survival in patients
with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion. …